DOPAMINE-BETA-HYDROXYLASE IMMUNOREACTIVITY IN HUMAN CEREBROSPINAL-FLUID - PROPERTIES, RELATIONSHIP TO CENTRAL NORADRENERGIC NEURONAL-ACTIVITY AND VARIATION IN PARKINSONS-DISEASE AND CONGENITAL DOPAMINE-BETA-HYDROXYLASE DEFICIENCY

被引:45
作者
OCONNOR, DT
CERVENKA, JH
STONE, RA
LEVINE, GL
PARMER, RJ
FRANCOBOURLAND, RE
MADRAZO, I
LANGLAIS, PJ
ROBERTSON, D
BIAGGIONI, I
机构
[1] UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103
[2] UNIV CALIF SAN DIEGO,DEPT NEUROSCI,SAN DIEGO,CA 92103
[3] DEPT VET AFFAIRS MED CTR,SAN DIEGO,CA
[4] INST NACL NUTR SALVADOR ZUBIRAN,DEPT BIOQUIM,MEXICO CITY 14000,DF,MEXICO
[5] INST MEXICANO SEGURO SOCIAL,CTR MED SIGLO XXI,DEPT INVEST CLIN NEUROL & NEUROCIRUGIA,MEXICO CITY,DF,MEXICO
[6] VANDERBILT UNIV,DEPT MED,NASHVILLE,TN
关键词
CEREBROSPINAL FLUID; DOPAMINE BETA-HYDROXYLASE; HYPERTENSION; METHOXYHYDROXYPHENYLGLYCOL; NORADRENALINE; PARKINSONS DISEASE; RADIOIMMUNOASSAY; RENAL FAILURE;
D O I
10.1042/cs0860149
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
1. Dopamine beta-hydroxylase is stored and released with catecholamines by exocytosis from secretory vesicles in noradrenergic neurons and chromaffin cells. Although dopamine beta-hydroxylase enzymic activity is measurable in cerebrospinal fluid, such activity is unstable, and its relationship to central noradrenergic neuronal activity in humans is not clearly established. To explore the significance of cerebrospinal fluid dopamine beta-hydroxylase, we applied a homologous human dopamine beta-hydroxylase radioimmunoassay to cerebrospinal fluid, in order to characterize the properties and stability of cerebrospinal fluid dopamine beta-hydroxylase, as well as its relationship to central noradrenergic neuronal activity and its variation in disease states such as hypertension, renal failure, Parkinsonism and congenital dopamine beta-hydroxylase deficiency. 2. Authentic, physically stable dopamine beta-hydroxylase immunoreactivity was present in normal human cerebrospinal fluid at a concentration of 31.3+/-1.4 ng/ml (range: 18.5-52.5 ng/ml), but at a 283+/-27-fold lower concentration than that found in plasma. Cerebrospinal fluid and plasma dopamine beta-hydroxylase concentrations were correlated (r=0.67, P=0.001). Some degree of local central nervous system control of cerebrospinal fluid dopamine beta-hydroxylase was suggested by incomplete correlation with plasma dopamine beta-hydroxylase (with an especially marked dissociation in renal disease) as well as the lack of a ventricular/lumbar cerebrospinal dopamine beta-hydroxylase concentration gradient. 3. Cerebrospinal fluid dopamine beta-hydroxylase was not changed by the central alpha(2)-agonist clonidine at a dose that diminished cerebrospinal fluid noradrenaline, nor did cerebrospinal fluid dopamine beta-hydroxylase correspond between subjects to cerebrospinal fluid concentrations of noradrenaline or methoxyhydroxyphenylglycol; thus, cerebrospinal fluid dopamine beta-hydroxylase concentration was not closely linked either pharmacologically or biochemically to central noradrenergic neuronal activity. 4. Cerebrospinal fluid dopamine beta-hydroxylase was not changed in essential hypertension. In Parkinson's disease, cerebrospinal fluid dopamine beta-hydroxy)ase was markedly diminished (16.3+/-2.9 versus 31.3+/-1.4 ng/ml, P<0.001) and rose by 58+/-21% (P=0.02) after adrenal-to-caudate chromaffin cell autografts. In congenital dopamine beta-hydroxylase deficiency, lack of detectable dopamine beta-hydroxylase immunoreactivity in cerebrospinal fluid or plasma suggests absent enzyme (rather than a catalytically defective enzyme) as the origin of the disorder. 5. We conclude that cerebrospinal fluid dopamine beta-hydroxylase immunoreactivity, while not closely linked to central noradrenergic neuronal activity, is at least in part derived from the central nervous system, and that its measurement may be useful in both the diagnosis and treatment of neurological disease.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 56 条
  • [1] CHROMOGRANIN-A - POSTTRANSLATIONAL MODIFICATIONS IN SECRETORY GRANULES
    BARBOSA, JA
    GILL, BM
    TAKIYYUDDIN, MA
    OCONNOR, DT
    [J]. ENDOCRINOLOGY, 1991, 128 (01) : 174 - 190
  • [2] DOPAMINE-BETA-HYDROXYLASE DEFICIENCY IN HUMANS
    BIAGGIONI, I
    GOLDSTEIN, DS
    ATKINSON, T
    ROBERTSON, D
    [J]. NEUROLOGY, 1990, 40 (02) : 370 - 373
  • [3] CEREBROSPINAL-FLUID AND PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN HUMAN HYPERTENSION
    CUBEDDU, LX
    DAVILA, J
    ZSCHAECK, D
    BARBELLA, YR
    ORDAZ, P
    DOMINGUEZ, J
    [J]. HYPERTENSION, 1981, 3 (04) : 448 - 455
  • [4] ALBUMIN EXCHANGE BETWEEN PLASMA AND CEREBROSPINAL FLUID
    CUTLER, RWP
    DEUEL, RK
    BARLOW, CF
    [J]. ARCHIVES OF NEUROLOGY, 1967, 17 (03) : 261 - &
  • [5] THE EFFECT OF DRUGS ON THE CONCENTRATION OF DOPAMINE BETA-HYDROXYLASE IN THE CEREBROSPINAL-FLUID OF RABBITS
    DEPOTTER, WP
    DEPOTTER, RW
    DESMET, FH
    DESCHAEPDRYVER, AF
    [J]. NEUROSCIENCE, 1980, 5 (11) : 1969 - 1977
  • [6] PRESENCE OF DOPAMINE BETA-HYDROXYLASE IN CEREBROSPINAL-FLUID OF RABBITS AND ITS INCREASED CONCENTRATION AFTER STIMULATION OF PERIPHERAL-NERVES AND COLD STRESS
    DEPOTTER, WP
    CHANH, CPH
    DESMET, F
    DESCHAEPDRYVER, AF
    [J]. NEUROSCIENCE, 1976, 1 (06) : 523 - 529
  • [7] DEPOTTER WP, 1978, ARCH INT PHARMACOD T, V232, P334
  • [8] DEPOTTER WP, 1969, J PHYSIOL-LONDON, V204, P102
  • [9] EVALUATION OF PARAMETERS FOR CENTRAL NEURONAL-ACTIVITY IN CEREBROSPINAL-FLUID OF RABBITS FOLLOWING YOHIMBINE
    DILLEN, L
    CLAEYS, M
    DEPOTTER, WP
    [J]. BIOCHEMICAL PHARMACOLOGY, 1986, 35 (22) : 3977 - 3982
  • [10] EFFECTS OF THE ALPHA-2-ANTAGONIST IDAZOXAN ON MONOAMINERGIC PARAMETERS MEASURED IN THE CEREBROSPINAL-FLUID OF RABBITS
    DILLEN, L
    CLAEYS, M
    DEPOTTER, WP
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 137 (01) : 33 - 40